uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Other Novel Therapies: Biomarkers, microRNAs and microRNA Inhibitors, DNA Methylation, Epigenetics, Immunotherapy and Virotherapy
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Endocrine Tumor Biology.
UCL Canc Inst, Med Genom Lab, Canc Res UK, London, England..
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Clinical Immunology.
2015 (English)In: Neuroendocrine Tumors: A Multidisciplinary Approach / [ed] Papotti, M; DeHerder, WW, S. Karger, 2015, 248-262 p.Chapter in book (Refereed)Text
Abstract [en]

Neuroendocrine tumors (NETs) consist of heterogeneous neoplasms. The neuroendocrine cells of the human body are confined to certain organs, such as the thyroid, pancreas and adrenals, or they are dispersed throughout the body in the respiratory tract and in the intestinal mucosa. The cells belong to the diffuse endocrine cell system, share a neuroendocrine phenotype, and accumulate precursor molecules which are then processed into hormones, peptides or amines. The tightly controlled release on stimulation is either to the blood stream or adjacent cells or neurons. Neuroendocrine cells regulate various processes in the human body, such as gastrointestinal secretion, blood pressure and response to stress. NETs present a wide spectrum of malignant diseases from rather benign to very malignant and lethal variants. NETs may occur in any organ, but are mainly detected in the gastroenteropancreatic system and in the lungs. The understanding of NET biology and treatments has changed dramatically during the last decade. Today, the main problems that clinicians and translational scientists face in overcoming these malignancies relate to various aspects within the molecular pathogenesis of NETs. This chapter focuses on the importance of novel biomarkers: microRNA and microRNA inhibitors; DNA methylation and epigenetics, and immunotherapy and virotherapy to develop novel treatments for NETs.

Place, publisher, year, edition, pages
S. Karger, 2015. 248-262 p.
, Frontiers of Hormone Research, ISSN 0301-3073 ; 44
National Category
Endocrinology and Diabetes Cancer and Oncology
URN: urn:nbn:se:uu:diva-284908DOI: 10.1159/000403885ISI: 000370334100018PubMedID: 26303717ISBN: 978-3-318-02773-0; 978-3-318-02772-3OAI: oai:DiVA.org:uu-284908DiVA: diva2:920962
Available from: 2016-04-19 Created: 2016-04-19 Last updated: 2016-04-19Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Giandomenico, ValeriaEssand, Magnus
By organisation
Endocrine Tumor BiologyClinical Immunology
Endocrinology and DiabetesCancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 109 hits
ReferencesLink to record
Permanent link

Direct link